Literature DB >> 20719952

HIV controllers with HLA-DRB1*13 and HLA-DQB1*06 alleles have strong, polyfunctional mucosal CD4+ T-cell responses.

April L Ferre1, Peter W Hunt, Delandy H McConnell, Megan M Morris, Juan C Garcia, Richard B Pollard, Hal F Yee, Jeffrey N Martin, Steven G Deeks, Barbara L Shacklett.   

Abstract

A small percentage of human immunodeficiency virus (HIV)-infected individuals, termed elite controllers, are able to spontaneously control HIV replication in blood. As the gastrointestinal mucosa is an important site of HIV transmission and replication as well as CD4+ T-cell depletion, it is important to understand the nature of the immune responses occurring in this compartment. Although the role of the HIV-specific CD8+ T-cell responses in mucosal tissues has been described, few studies have investigated the role of mucosal HIV-specific CD4+ T cells. In this study, we assessed HIV-specific CD4+ T-cell responses in the rectal mucosa of 28 "controllers" (viral load [VL] of <2,000 copies/ml), 14 "noncontrollers" (VL of >10,000 copies/ml), and 10 individuals on highly active antiretroviral therapy (HAART) (VL of <75 copies/ml). Controllers had higher-magnitude Gag-specific mucosal CD4+ T-cell responses than individuals on HAART (P<0.05), as measured by their ability to produce gamma interferon (IFN-γ), interleukin-2 (IL-2), tumor necrosis factor alpha (TNF-α), and macrophage inflammatory protein 1β (MIP-1β). The frequency of polyfunctional mucosal CD4+ T cells was also higher in controllers than in noncontrollers or individuals on HAART (P<0.05). Controllers with the strongest HIV-specific CD4+ T-cell responses possessed class II HLA alleles, HLA-DRB1*13 and/or HLA-DQB1*06, previously associated with a nonprogression phenotype. Strikingly, individuals with both HLA-DRB1*13 and HLA-DQB1*06 had highly polyfunctional mucosal CD4+ T cells compared to individuals with HLA-DQB1*06 alone or other class II alleles. The frequency of polyfunctional CD4+ T cells in rectal mucosa positively correlated with the magnitude of the mucosal CD8+ T-cell response (Spearman's r=0.43, P=0.005), suggesting that increased CD4+ T-cell "help" may be important in maintaining strong CD8+ T-cell responses in the gut of HIV controllers.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20719952      PMCID: PMC2953185          DOI: 10.1128/JVI.00980-10

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  57 in total

Review 1.  The role of CD4(+) T helper cells in the cytotoxic T lymphocyte response to HIV-1.

Authors:  M Altfeld; E S Rosenberg
Journal:  Curr Opin Immunol       Date:  2000-08       Impact factor: 7.486

2.  Expansion of pre-existing, lymph node-localized CD8+ T cells during supervised treatment interruptions in chronic HIV-1 infection.

Authors:  Marcus Altfeld; Jan van Lunzen; Nicole Frahm; Xu G Yu; Claus Schneider; Robert L Eldridge; Margaret E Feeney; Dirk Meyer-Olson; Hans-Juergen Stellbrink; Bruce D Walker
Journal:  J Clin Invest       Date:  2002-03       Impact factor: 14.808

3.  Immunodominant HIV-specific CD8+ T-cell responses are common to blood and gastrointestinal mucosa, and Gag-specific responses dominate in rectal mucosa of HIV controllers.

Authors:  April L Ferre; Donna Lemongello; Peter W Hunt; Megan M Morris; Juan Carlos Garcia; Richard B Pollard; Hal F Yee; Jeffrey N Martin; Steven G Deeks; Barbara L Shacklett
Journal:  J Virol       Date:  2010-07-28       Impact factor: 5.103

4.  Loss of CD4+ T cell proliferative ability but not loss of human immunodeficiency virus type 1 specificity equates with progression to disease.

Authors:  J D Wilson; N Imami; A Watkins; J Gill; P Hay; B Gazzard; M Westby; F M Gotch
Journal:  J Infect Dis       Date:  2000-08-17       Impact factor: 5.226

5.  Role for HLA class II molecules in HIV-1 suppression and cellular immunity following antiretroviral treatment.

Authors:  U Malhotra; S Holte; S Dutta; M M Berrey; E Delpit; D M Koelle; A Sette; L Corey; M J McElrath
Journal:  J Clin Invest       Date:  2001-02       Impact factor: 14.808

6.  Novel, cross-restricted, conserved, and immunodominant cytotoxic T lymphocyte epitopes in slow progressors in HIV type 1 infection.

Authors:  P J Goulder; M Bunce; P Krausa; K McIntyre; S Crowley; B Morgan; A Edwards; P Giangrande; R E Phillips; A J McMichael
Journal:  AIDS Res Hum Retroviruses       Date:  1996-12-10       Impact factor: 2.205

7.  Presence of HIV-1 Gag-specific IFN-gamma+IL-2+ and CD28+IL-2+ CD4 T cell responses is associated with nonprogression in HIV-1 infection.

Authors:  Mark J Boaz; Anele Waters; Shahed Murad; Philippa J Easterbrook; Annapurna Vyakarnam
Journal:  J Immunol       Date:  2002-12-01       Impact factor: 5.422

8.  Optimization of methods to assess human mucosal T-cell responses to HIV infection.

Authors:  Barbara L Shacklett; Otto Yang; Mary Ann Hausner; Julie Elliott; Lance Hultin; Charles Price; Marie Fuerst; Jose Matud; Patricia Hultin; Catherine Cox; Javier Ibarrondo; Johnson T Wong; Douglas F Nixon; Peter A Anton; Beth D Jamieson
Journal:  J Immunol Methods       Date:  2003-08       Impact factor: 2.303

Review 9.  The influence of HLA genotype on AIDS.

Authors:  Mary Carrington; Stephen J O'Brien
Journal:  Annu Rev Med       Date:  2001-12-03       Impact factor: 13.739

10.  Skewed representation of functionally distinct populations of virus-specific CD4 T cells in HIV-1-infected subjects with progressive disease: changes after antiretroviral therapy.

Authors:  Alexandre Harari; Stéphanie Petitpierre; Florence Vallelian; Giuseppe Pantaleo
Journal:  Blood       Date:  2003-09-04       Impact factor: 22.113

View more
  63 in total

1.  HLA-DQB1*06 and breadth of Nef core region-specific T-cell response are associated with slow disease progression in antiretroviral therapy-naive Chinese HIV-1 subtype B patients.

Authors:  Weihua Li; Chuanyun Li; Wei Xia; Xiuhui Li
Journal:  Hum Vaccin Immunother       Date:  2017-10-03       Impact factor: 3.452

2.  In vitro sensitization of T cells with DC-associated/delivered HIV constructs can induce a polyfunctional CTL response, memory T-cell response, and virus suppression.

Authors:  Swarali Kurle; Madhuri Thakar; Ashwini Shete; Ramesh Paranjape
Journal:  Viral Immunol       Date:  2012-01-10       Impact factor: 2.257

Review 3.  Unravelling the mechanisms of durable control of HIV-1.

Authors:  Bruce D Walker; Xu G Yu
Journal:  Nat Rev Immunol       Date:  2013-07       Impact factor: 53.106

4.  Increased frequency of regulatory T cells accompanies increased immune activation in rectal mucosae of HIV-positive noncontrollers.

Authors:  Julia M Shaw; Peter W Hunt; J William Critchfield; Delandy H McConnell; Juan Carlos Garcia; Richard B Pollard; Ma Somsouk; Steven G Deeks; Barbara L Shacklett
Journal:  J Virol       Date:  2011-08-31       Impact factor: 5.103

Review 5.  Success and failure of the cellular immune response against HIV-1.

Authors:  Stephen A Migueles; Mark Connors
Journal:  Nat Immunol       Date:  2015-06       Impact factor: 25.606

6.  Conservation of HIV-1 T cell epitopes across time and clades: validation of immunogenic HLA-A2 epitopes selected for the GAIA HIV vaccine.

Authors:  Lauren Levitz; Ousmane A Koita; Kotou Sangare; Matthew T Ardito; Christine M Boyle; John Rozehnal; Karamoko Tounkara; Sounkalo M Dao; Youssouf Koné; Zoumana Koty; Soren Buus; Leonard Moise; William D Martin; Anne S De Groot
Journal:  Vaccine       Date:  2012-10-24       Impact factor: 3.641

Review 7.  Tissue issues: mucosal T-cell responses in HIV-1 infection.

Authors:  Barbara L Shacklett; April L Ferre; Brenna E Kiniry
Journal:  Curr Opin HIV AIDS       Date:  2019-03       Impact factor: 4.283

8.  Modulation of nonneutralizing HIV-1 gp41 responses by an MHC-restricted TH epitope overlapping those of membrane proximal external region broadly neutralizing antibodies.

Authors:  Jinsong Zhang; S Munir Alam; Hilary Bouton-Verville; Yao Chen; Amanda Newman; Shelley Stewart; Frederick H Jaeger; David C Montefiori; S Moses Dennison; Barton F Haynes; Laurent Verkoczy
Journal:  J Immunol       Date:  2014-01-24       Impact factor: 5.422

9.  A DNA vaccine encoding multiple HIV CD4 epitopes elicits vigorous polyfunctional, long-lived CD4+ and CD8+ T cell responses.

Authors:  Daniela Santoro Rosa; Susan Pereira Ribeiro; Rafael Ribeiro Almeida; Eliane Conti Mairena; Edilberto Postól; Jorge Kalil; Edecio Cunha-Neto
Journal:  PLoS One       Date:  2011-02-11       Impact factor: 3.240

10.  Robust immunity to an auxotrophic Mycobacterium bovis BCG-VLP prime-boost HIV vaccine candidate in a nonhuman primate model.

Authors:  Gerald K Chege; Wendy A Burgers; Helen Stutz; Ann E Meyers; Rosamund Chapman; Agano Kiravu; Rubina Bunjun; Enid G Shephard; William R Jacobs; Edward P Rybicki; Anna-Lise Williamson
Journal:  J Virol       Date:  2013-02-28       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.